webmaster0593

As precision oncology shifts toward non-invasive monitoring, the EU-funded SANGUINE project reports major multi-centre validation milestones for its sequencing-free epigenetic liquid biopsy platform. By profiling 5-mC and 5-hmC biomarkers from peripheral blood and cfDNA, the HemaChip microfluidic array bypasses the clinical and economic bottlenecks of traditional NGS—delivering a decentralised, high-sensitivity diagnostic and serial MRD monitoring workflow in just 2–3 days for €250 per test.

The recent promo video released by Tel-Aviv University offers a clear window into the groundbreaking work behind the SANGUINE project.

The SANGUINE Project represents a significant advancement in the early detection of hematological malignancies. This initiative aims to transform cancer care across Europe by introducing a cutting-edge blood test designed to identify blood cancers at their earliest stages. Early detection is crucial for improving patient outcomes and quality of life, and the SANGUINE Project is poised to become a standard tool in clinical practice. Biomarker Project Overview: The Foundation of SANGUINE...